First Time Loading...

Novo Nordisk A/S
NYSE:NVO

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
NYSE:NVO
Watchlist
Price: 122.75 USD -1.43% Market Closed
Updated: Apr 19, 2024

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Novo Nordisk A/S

Revenue
232.3B DKK
Cost of Revenue
-35.8B DKK
Gross Profit
196.5B DKK
Operating Expenses
-91.8B DKK
Operating Income
104.7B DKK
Other Expenses
-21B DKK
Net Income
83.7B DKK

Margins Comparison
Novo Nordisk A/S Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK
85%
45%
36%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
708.2B USD
79%
30%
15%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
350.8B USD
69%
28%
41%
US
Merck & Co Inc
NYSE:MRK
317B USD
74%
7%
1%
UK
AstraZeneca PLC
LSE:AZN
167.5B GBP
82%
19%
13%
CH
Roche Holding AG
SIX:ROG
174.6B CHF
74%
33%
20%
CH
Novartis AG
SIX:NOVN
172.2B CHF
74%
27%
32%
US
Pfizer Inc
NYSE:PFE
143.4B USD
70%
22%
4%
FR
Sanofi SA
PAR:SAN
107.7B EUR
69%
22%
12%
Country DK
Market Cap 3.8T DKK
Gross Margin
85%
Operating Margin
45%
Net Margin
36%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 708.2B USD
Gross Margin
79%
Operating Margin
30%
Net Margin
15%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country US
Market Cap 350.8B USD
Gross Margin
69%
Operating Margin
28%
Net Margin
41%
Country US
Market Cap 317B USD
Gross Margin
74%
Operating Margin
7%
Net Margin
1%
Country UK
Market Cap 167.5B GBP
Gross Margin
82%
Operating Margin
19%
Net Margin
13%
Country CH
Market Cap 174.6B CHF
Gross Margin
74%
Operating Margin
33%
Net Margin
20%
Country CH
Market Cap 172.2B CHF
Gross Margin
74%
Operating Margin
27%
Net Margin
32%
Country US
Market Cap 143.4B USD
Gross Margin
70%
Operating Margin
22%
Net Margin
4%
Country FR
Market Cap 107.7B EUR
Gross Margin
69%
Operating Margin
22%
Net Margin
12%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Novo Nordisk A/S Competitors

Country Company Market Cap ROE ROA ROCE ROIC
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK
88%
30%
79%
36%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
708.2B USD
49%
9%
30%
16%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
350.8B USD
49%
21%
19%
16%
US
Merck & Co Inc
NYSE:MRK
317B USD
1%
0%
5%
1%
UK
AstraZeneca PLC
LSE:AZN
167.5B GBP
16%
6%
13%
11%
CH
Roche Holding AG
SIX:ROG
174.6B CHF
40%
13%
30%
23%
CH
Novartis AG
SIX:NOVN
172.2B CHF
28%
14%
16%
14%
US
Pfizer Inc
NYSE:PFE
143.4B USD
2%
1%
8%
14%
FR
Sanofi SA
PAR:SAN
107.7B EUR
7%
4%
10%
8%
Country DK
Market Cap 3.8T DKK
ROE
88%
ROA
30%
ROCE
79%
ROIC
36%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 708.2B USD
ROE
49%
ROA
9%
ROCE
30%
ROIC
16%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country US
Market Cap 350.8B USD
ROE
49%
ROA
21%
ROCE
19%
ROIC
16%
Country US
Market Cap 317B USD
ROE
1%
ROA
0%
ROCE
5%
ROIC
1%
Country UK
Market Cap 167.5B GBP
ROE
16%
ROA
6%
ROCE
13%
ROIC
11%
Country CH
Market Cap 174.6B CHF
ROE
40%
ROA
13%
ROCE
30%
ROIC
23%
Country CH
Market Cap 172.2B CHF
ROE
28%
ROA
14%
ROCE
16%
ROIC
14%
Country US
Market Cap 143.4B USD
ROE
2%
ROA
1%
ROCE
8%
ROIC
14%
Country FR
Market Cap 107.7B EUR
ROE
7%
ROA
4%
ROCE
10%
ROIC
8%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More